Selank (5mg & 10mg)

Selank (10mg): A Synthetic Anxiolytic and Nootropic Peptide — a Heptapeptide Analogue of the Human Immunomodulatory Peptide Tuftsin (Thr-Lys-Pro-Arg) with the Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, Designed to Provide Anxiolytic (Anti-Anxiety), Nootropic (Cognitive-Enhancing), Neuroprotective, and Immunomodulatory Effects with a Favorable Safety Profile and Low Abuse Potential — the 10mg Vial Format for Investigational Research in Anxiety Disorders, Cognitive Enhancement, Neuroprotection, Stress Resilience, and Neuropsychopharmacology

Selank is a synthetic heptapeptide (7 amino acids) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) — it is an analogue of the human endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg, TKPR), which is a naturally occurring immunomodulatory peptide produced in the spleen by enzymatic cleavage of the IgG heavy chain. Selank was developed by Russian researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s, as part of a research program to develop peptide-based drugs with anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) effects, building on earlier work with tuftsin and related peptides (including the related peptide Semax, a heptapeptide analogue of ACTH [adrenocorticotropic hormone] with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, which is also a nootropic/neuroprotective peptide developed by the same Russian research group). Selank was designed by extending the tuftsin tetrapeptide sequence (TKPR) with a C-terminal tripeptide extension (Pro-Gly-Pro, PGP) — this extension was chosen because the Pro-Gly-Pro motif is known to confer metabolic stability (resistance to peptidase degradation), enhance blood-brain barrier penetration, and modulate the peptide's pharmacological profile, resulting in a peptide with potent anxiolytic and nootropic effects, good stability, and a favorable safety profile. Selank has been extensively studied in preclinical and clinical research in Russia and Eastern Europe, where it has been approved as a pharmaceutical drug (under the brand name Selank) for the treatment of generalized anxiety disorder (GAD) and other anxiety-related conditions, and it is also used off-label for cognitive enhancement, stress resilience, neuroprotection, and as an adjunct in the treatment of depression, insomnia, and other neuropsychiatric conditions. Outside of Russia/Eastern Europe, Selank is primarily available as a research-grade peptide/investigational compound for laboratory and preclinical research, and it is not FDA-approved in the United States or approved by the EMA in Europe for any indication (though it is being studied in clinical trials and is available as a research chemical). Selank exerts its biological effects through several interconnected mechanisms: (1) Anxiolytic effects via modulation of the GABAergic system — Selank has been shown to modulate the GABA (gamma-aminobutyric acid) neurotransmitter system, particularly by increasing the expression and function of GABA-A receptors and enhancing GABAergic neurotransmission in brain regions involved in anxiety regulation (amygdala, hippocampus, prefrontal cortex); this is a key mechanism for its anti-anxiety effects, though Selank does NOT bind directly to GABA-A receptors (unlike benzodiazepines) and does not cause sedation, dependence, or abuse potential; (2) Nootropic effects via modulation of monoamine and neuropeptide systems — Selank modulates the levels and turnover of key neurotransmitters including serotonin, dopamine, and norepinephrine in brain regions involved in cognition, mood, and motivation (prefrontal cortex, hippocampus, striatum); it also increases the expression of brain-derived neurotrophic factor (BDNF) and other neurotrophic factors, promoting neuronal plasticity, learning, and memory; (3) Neuroprotective effects — Selank has demonstrated neuroprotective effects in preclinical models of neurodegeneration, oxidative stress, excitotoxicity, and traumatic brain injury, through mechanisms including: reduction of oxidative stress and reactive oxygen species (ROS), inhibition of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6), modulation of apoptotic pathways (reducing neuronal apoptosis), enhancement of mitochondrial function, and promotion of neurotrophic factor expression (BDNF, NGF); (4) Immunomodulatory effects — as an analogue of tuftsin (a known immunomodulatory peptide), Selank retains immunomodulatory activity, including modulation of immune cell function (macrophages, lymphocytes, natural killer cells), regulation of cytokine production, and enhancement of immune surveillance; these immunomodulatory effects may contribute to its neuroprotective effects (by reducing neuroinflammation) and to its overall effects on stress resilience (since stress and immune function are closely linked); (5) Stress resilience and HPA axis modulation — Selank has been shown to modulate the hypothalamic-pituitary-adrenal (HPA) axis, the body's primary stress response system; it can reduce excessive cortisol release in response to stress, promote a more balanced stress response, and enhance stress resilience (the ability to cope with and recover from stress); this is a key mechanism for its anxiolytic effects and for its potential benefits in stress-related disorders; (6) Metabolic stability and blood-brain barrier penetration — the Pro-Gly-Pro C-terminal extension confers resistance to peptidase degradation (giving Selank a longer half-life and better bioavailability than tuftsin), and Selank has been shown to effectively cross the blood-brain barrier (BBB) to exert its central nervous system effects; (7) Additional effects — Selank may also have mild antidepressant effects (via modulation of serotonin and other monoamine systems), sleep-regulating effects (by reducing anxiety and promoting relaxation without sedation), analgesic (pain-relieving) effects (via modulation of pain pathways and the endogenous opioid system), and metabolic effects (modulation of appetite and energy metabolism, though these are less well-characterized). Selank is typically administered by subcutaneous (SC) or intranasal (IN) injection/application — in its pharmaceutical form in Russia, Selank is available as an intranasal spray (the most common route of administration for its anxiolytic indication, as it provides rapid absorption and direct nose-to-brain delivery) and as an injectable formulation; in research settings, it is typically reconstituted from lyophilized powder and administered by subcutaneous injection (the most common route for research-grade peptide use) or intranasally. The 10mg vial format of Selank provides a convenient quantity for research use, allowing investigators to explore a range of doses and administration routes. Selank is widely regarded as having a very favorable safety profile — in preclinical and clinical studies, Selank has been shown to be well-tolerated, with minimal side effects, no significant toxicity (even at high doses), no sedation (unlike benzodiazepines), no cognitive impairment, no dependence or withdrawal effects, no abuse potential (it is not a controlled substance), and no significant drug-drug interactions (it does not significantly inhibit or induce cytochrome P450 enzymes). Common side effects (usually mild and transient) may include: mild headache, mild nausea (especially at higher doses or with rapid administration), mild dizziness, fatigue or drowsiness (at high doses, though Selank is generally non-sedating), mild anxiety or restlessness (in rare cases, particularly at initiation), injection site reactions (pain, redness, swelling with SC injection), and mild nasal irritation (with intranasal administration). Contraindications include: known hypersensitivity to Selank or any of its components, pregnancy and breastfeeding (insufficient safety data), severe liver or kidney impairment (use caution, may require dose adjustment), and children/adolescents (not studied in pediatric populations). Selank should be used with caution in individuals with bipolar disorder (may theoretically affect mood, though no significant mood destabilization has been reported), seizure disorders (use caution, though no pro-convulsant effects have been demonstrated), and in individuals taking other CNS-active medications (monitor for additive effects, though interactions are generally minimal). As of 2026, Selank is NOT FDA-approved in the United States for any indication — it is a research-grade/investigational compound in the US and most Western countries, though it is approved as a pharmaceutical drug in Russia and some Eastern European countries for generalized anxiety disorder. The research-grade Selank supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Selank: A Comprehensive Analysis of Its Pharmacology, Mechanisms of Action, Clinical Research, and Practical Research Considerations

1. The molecular structure and design rationale of Selank: from tuftsin to a stabilized anxiolytic/nootropic heptapeptide: Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP) is a synthetic heptapeptide designed as an analogue of the endogenous human tetrapeptide tuftsin (Thr-Lys-Pro-Arg, TKPR). To understand Selank's design, it is essential to understand tuftsin: (a) Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that was discovered in 1970 by Najjar and Nishioka; it is produced in the spleen by the enzymatic cleavage of the Fc portion of the IgG heavy chain (specifically, the sequence Thr-Lys-Pro-Arg is located in the CH2 domain of IgG, and it is released by the action of two enzymes: leukokininase (on the spleen cell membrane) and carboxypeptidase B [in the serum]); tuftsin is a potent immunomodulatory peptide that binds to specific receptors on immune cells (neutrophils, monocytes/macrophages, lymphocytes, natural killer cells) and stimulates their function — including phagocytosis, chemotaxis, oxidative burst, cytokine production, and antigen presentation; tuftsin also has some central nervous system effects (it can cross the BBB and has been shown to have some nootropic and anxiolytic effects in preclinical studies), but its use as a therapeutic is limited by its very short half-life (it is rapidly degraded by peptidases in the blood and tissues, with a half-life of only a few minutes) and its primarily peripheral (immune) effects with relatively weak central effects; (b) The design of Selank — Russian researchers at the Institute of Molecular Genetics (led by Professor N.F. Myasoedov and colleagues) designed Selank by extending the tuftsin tetrapeptide sequence (TKPR) with a C-terminal tripeptide extension: Pro-Gly-Pro (PGP); this specific extension was chosen for several reasons: (i) Metabolic stability — the Pro-Gly-Pro motif is known to confer resistance to degradation by exopeptidases and many endopeptidases; the proline residues create conformational constraints that make the peptide less susceptible to enzymatic cleavage, and the C-terminal proline prevents carboxypeptidase degradation; this significantly extends Selank's half-life compared to tuftsin (from minutes to hours), improving its bioavailability and therapeutic utility; (ii) Blood-brain barrier penetration — the Pro-Gly-Pro motif has been shown to enhance the transport of peptides across the blood-brain barrier (this motif is found in several known BBB-penetrating peptides, and the conformational flexibility and specific amino acid composition [proline, glycine] facilitate interactions with BBB transporters or passive diffusion); this is critical for Selank's central effects (anxiolytic, nootropic, neuroprotective); (iii) Pharmacological modulation — the Pro-Gly-Pro extension modulates the peptide's pharmacological profile, shifting the balance from primarily immunomodulatory (tuftsin) to a combination of anxiolytic, nootropic, neuroprotective, and immunomodulatory effects (Selank); the extension may alter the peptide's receptor binding profile, its interaction with neurotransmitter systems, and its overall CNS effects; (iv) Structural homology with Semax — it is notable that the related peptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP), developed by the same research group, also has the C-terminal Pro-Gly-Pro extension (in Semax's case, extending the ACTH 4-7 tetrapeptide [Met-Glu-His-Phe] with Pro-Gly-Pro); this Pro-Gly-Pro extension is a deliberate design motif used by this research group to create stabilized, BBB-penetrating peptide analogues with enhanced pharmacological profiles; (c) Selank's physicochemical properties — Selank is a 7-amino-acid peptide with a molecular weight of approximately 751.9 Da; it has a net positive charge at physiological pH (due to the lysine and arginine residues), which contributes to its solubility in water and its interactions with cell membranes and receptors; it is highly soluble in water and aqueous solutions, making it easy to reconstitute and administer; it is stable as a lyophilized powder for long-term storage, and stable in reconstituted solution for 14-30 days under refrigeration; (d) Structure-activity relationship (SAR) — structure-activity relationship studies have shown that: (i) the N-terminal Thr-Lys-Pro-Arg (tuftsin) sequence is essential for the peptide's immunomodulatory activity and contributes to its anxiolytic/nootropic effects; (ii) the C-terminal Pro-Gly-Pro extension is essential for metabolic stability, BBB penetration, and the full expression of the peptide's central effects; (iii) modifications to specific residues can alter the peptide's activity profile — for example, acetylation of the N-terminus or amidation of the C-terminus can further enhance stability, while substitutions at specific positions can modulate receptor selectivity; (iv) the overall conformation of the peptide (influenced by the proline residues, which create turns and conformational constraints) is important for receptor binding and biological activity; understanding Selank's molecular structure and design rationale is essential for appreciating its unique pharmacological profile — it is not simply "tuftsin with extra amino acids," but a rationally designed peptide that combines the immunomodulatory core of tuftsin with a stabilizing, BBB-penetrating, pharmacologically-modulating C-terminal extension to create a peptide with potent and diverse central nervous system effects (anxiolytic, nootropic, neuroprotective) alongside its retained immunomodulatory activity.
2. Deep dive into the mechanisms of action: GABAergic modulation, monoamine regulation, neurotrophic factor expression, HPA axis modulation, and immunomodulation: Selank exerts its diverse pharmacological effects through multiple interconnected mechanisms that work synergistically to produce its anxiolytic, nootropic, neuroprotective, and immunomodulatory effects. Understanding these mechanisms in detail is essential for appreciating Selank's unique profile and its potential therapeutic applications: (a) GABAergic system modulation (anxiolytic mechanism): GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system, and the GABAergic system plays a critical role in the regulation of anxiety, stress, arousal, and neuronal excitability. Selank modulates the GABAergic system through several mechanisms: (i) Increased GABA-A receptor expression — preclinical studies have shown that Selank administration increases the expression of GABA-A receptor subunits (particularly α2, α3, and γ2 subunits, which are associated with anxiolytic effects without sedation) in brain regions involved in anxiety regulation (amygdala, hippocampus, prefrontal cortex, periaqueductal gray); (ii) Enhanced GABAergic neurotransmission — Selank enhances GABAergic inhibitory neurotransmission, increasing the inhibitory tone in anxiety-related brain circuits and reducing excessive neuronal excitability associated with anxiety; (iii) Modulation of GABA synthesis and turnover — Selank may modulate the activity of glutamic acid decarboxylase (GAD, the enzyme that synthesizes GABA from glutamate) and GABA transaminase (GABA-T, the enzyme that degrades GABA), thereby increasing GABA levels and enhancing GABAergic function; (iv) Important distinction from benzodiazepines — critically, Selank does NOT bind directly to the benzodiazepine binding site on the GABA-A receptor (unlike diazepam, alprazolam, lorazepam, and other benzodiazepines); instead, it modulates GABAergic function indirectly (through receptor expression, neurotransmitter levels, and downstream signaling); this is why Selank has anxiolytic effects WITHOUT causing sedation, cognitive impairment, muscle relaxation, dependence, withdrawal, or abuse potential — it enhances GABAergic function in a more physiological, receptor-subtype-selective manner rather than the broad, non-specific GABA-A potentiation caused by benzodiazepines; (v) Anxiolytic brain regions — Selank's GABAergic effects are particularly prominent in the amygdala (the brain's fear/anxiety center), the hippocampus (which regulates contextual fear and stress responses), the prefrontal cortex (which regulates top-down control of anxiety and emotional regulation), and the periaqueductal gray (which regulates panic and defensive behaviors); (b) Monoamine neurotransmitter modulation (nootropic and antidepressant mechanism): Selank modulates the levels, turnover, and receptor function of key monoamine neurotransmitters — serotonin (5-HT), dopamine (DA), and norepinephrine (NE) — which are critically involved in the regulation of mood, cognition, motivation, attention, arousal, and stress responses: (i) Serotonin (5-HT) modulation — Selank modulates serotonergic neurotransmission, increasing serotonin levels and turnover in the prefrontal cortex, hippocampus, and striatum; it may modulate the activity of the serotonin transporter (SERT) and the expression of serotonin receptors (particularly 5-HT1A and 5-HT2C receptors, which are involved in anxiety and mood regulation); the serotonergic effects contribute to Selank's anxiolytic, antidepressant, and anti-compulsive effects; (ii) Dopamine (DA) modulation — Selank modulates dopaminergic neurotransmission, increasing dopamine levels and turnover in the prefrontal cortex (involved in cognition, attention, and executive function), hippocampus (involved in learning and memory), and striatum (involved in motivation, reward, and movement); it may modulate the dopamine transporter (DAT) and dopamine receptor expression (particularly D1 and D2 receptors); the dopaminergic effects contribute to Selank's nootropic (cognitive-enhancing), motivation-enhancing, and antidepressant effects; (iii) Norepinephrine (NE) modulation — Selank modulates noradrenergic neurotransmission, increasing norepinephrine levels and turnover in the prefrontal cortex and hippocampus; it may modulate the norepinephrine transporter (NET) and adrenergic receptor expression; the noradrenergic effects contribute to Selank's nootropic (attention, alertness, working memory), stress-resilience, and antidepressant effects; (iv) Balanced modulation — importantly, Selank produces a BALANCED modulation of these monoamine systems rather than a massive, non-specific increase (as seen with some stimulants or antidepressants); it tends to normalize monoamine function — increasing levels that are low (e.g., in stress or depression) without causing excessive elevation (which could cause anxiety, agitation, or insomnia); this balanced modulation is why Selank has nootropic and antidepressant effects without causing jitteriness, insomnia, or the "high" associated with stimulants; (c) Neurotrophic factor expression and neuroplasticity (nootropic and neuroprotective mechanism): Selank increases the expression of brain-derived neurotrophic factor (BDNF) and other neurotrophic factors (nerve growth factor [NGF], glial cell line-derived neurotrophic factor [GDNF], insulin-like growth factor-1 [IGF-1]) in the brain, particularly in the hippocampus and prefrontal cortex: (i) BDNF is the most well-studied neurotrophic factor in the context of cognition and mental health; it promotes neuronal survival, differentiation, and plasticity; it is critical for long-term potentiation (LTP — the cellular basis of learning and memory), synaptic plasticity, and neurogenesis (the formation of new neurons, particularly in the hippocampal dentate gyrus); BDNF levels are reduced in depression, anxiety, chronic stress, and neurodegenerative diseases, and increasing BDNF is a key mechanism of action of many antidepressants (SSRIs, SNRIs) and cognitive enhancers; (ii) Mechanism of BDNF increase — Selank increases BDNF expression through several pathways: activation of the cAMP/CREB (cAMP response element-binding protein) signaling pathway (CREB is a transcription factor that binds to the BDNF gene promoter and increases BDNF transcription), modulation of monoamine signaling (which can activate CREB and increase BDNF), reduction of oxidative stress and inflammation (which can otherwise suppress BDNF expression), and direct effects on gene expression; (iii) Functional consequences — increased BDNF and neurotrophic factor expression leads to: enhanced synaptic plasticity and LTP (improved learning and memory), increased hippocampal neurogenesis (improved mood and cognition), enhanced neuronal survival (neuroprotection), and improved overall brain function and resilience; (d) HPA axis modulation and stress resilience (anxiolytic and stress-protective mechanism): The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary neuroendocrine stress response system; in response to stress, the hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the pituitary to release adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to release cortisol (the primary stress hormone in humans); while acute cortisol release is adaptive (providing energy and focus during stress), chronic or excessive cortisol release (as seen in chronic stress, anxiety disorders, and depression) is harmful — it causes hippocampal atrophy, impaired cognition, increased anxiety, depression, immune suppression, metabolic disturbances, and cardiovascular disease; Selank modulates the HPA axis to promote a more balanced, adaptive stress response: (i) Reduced excessive cortisol release — Selank has been shown to reduce excessive cortisol release in response to acute and chronic stress in preclinical models; it does NOT completely suppress cortisol (which would be harmful — cortisol is essential for life), but it prevents the excessive, pathological elevation of cortisol that occurs in chronic stress and anxiety; (ii) Enhanced negative feedback — Selank may enhance the negative feedback sensitivity of the HPA axis (the mechanism by which cortisol normally suppresses further CRH/ACTH release, preventing excessive cortisol elevation); in chronic stress and anxiety, this negative feedback can become impaired, leading to excessive cortisol; Selank may restore normal negative feedback sensitivity; (iii) CRH modulation — Selank may modulate the release and activity of CRH (corticotropin-releasing hormone), the primary hypothalamic driver of the HPA axis; CRH is also directly anxiogenic (it promotes anxiety when released in the amygdala and other brain regions), and reducing excessive CRH release contributes to Selank's anxiolytic effects; (iv) Stress resilience — by modulating the HPA axis and reducing excessive stress hormone release, Selank enhances stress resilience — the ability to cope with, adapt to, and recover from stress without developing pathological anxiety, depression, or stress-related physical illness; this is a key therapeutic benefit for individuals with chronic stress, anxiety disorders, burnout, and stress-related conditions; (e) Immunomodulation and anti-neuroinflammation (neuroprotective and stress-resilience mechanism): As an analogue of tuftsin (a known immunomodulatory peptide), Selank retains significant immunomodulatory activity, which contributes to its neuroprotective effects and overall health benefits: (i) Immune cell modulation — Selank modulates the function of immune cells including macrophages/monocytes, lymphocytes (T cells, B cells), natural killer (NK) cells, and neutrophils; it can enhance immune surveillance and function (particularly in states of immune suppression, such as chronic stress, aging, or illness) while also modulating excessive or pathological immune activation (inflammation); (ii) Cytokine regulation — Selank regulates the production of cytokines (signaling molecules of the immune system); it can reduce the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) in states of excessive inflammation, while promoting the production of anti-inflammatory cytokines (IL-10, TGF-β) and immunoregulatory cytokines; this balanced immunomodulation is important because chronic low-grade inflammation (including neuroinflammation — inflammation in the brain) is increasingly recognized as a contributor to anxiety, depression, cognitive decline, and neurodegenerative diseases; (iii) Anti-neuroinflammation — Selank's ability to reduce pro-inflammatory cytokine production in the brain (by modulating microglia — the brain's resident immune cells — and by reducing peripheral inflammation that can affect the brain) contributes to its neuroprotective and psychotropic effects; neuroinflammation is now recognized as a key factor in the pathophysiology of depression, anxiety, PTSD, Alzheimer's disease, Parkinson's disease, and other neuropsychiatric/neurodegenerative conditions, and reducing neuroinflammation is a promising therapeutic strategy; (iv) Stress-immune interaction — chronic stress suppresses immune function (via cortisol and sympathetic nervous system activation), and immune dysfunction can contribute to stress-related mental health problems; Selank's dual effects on stress regulation (HPA axis) and immune function (immunomodulation) make it particularly effective for stress-related conditions where both systems are dysregulated; (f) Additional mechanisms: (i) Antioxidant effects — Selank reduces oxidative stress and reactive oxygen species (ROS) production, enhances endogenous antioxidant defenses (superoxide dismutase [SOD], catalase, glutathione), and reduces lipid peroxidation; oxidative stress is a key contributor to neurodegeneration, aging, and mental illness, and Selank's antioxidant effects contribute to its neuroprotective and cognitive-enhancing effects; (ii) Mitochondrial function enhancement — Selank may enhance mitochondrial function and energy metabolism in neurons, improving neuronal energy status and resilience; (iii) Apoptosis modulation — Selank modulates apoptotic (programmed cell death) pathways, reducing excessive neuronal apoptosis in conditions of stress, toxicity, or neurodegeneration; (iv) Endogenous opioid system modulation — Selank may modulate the endogenous opioid system (enkephalins, endorphins), which could contribute to its anxiolytic, analgesic, and mood-enhancing effects (though Selank does not bind directly to opioid receptors and does not cause opioid-like effects or dependence); (v) Gene expression modulation — Selank modulates the expression of numerous genes involved in neurotransmission, neuroplasticity, inflammation, stress response, and cell survival, through effects on transcription factors (CREB, NF-κB, AP-1) and epigenetic mechanisms; in summary, Selank's mechanisms of action are diverse and interconnected — it is not a "single-target" drug (like an SSRI, which primarily targets the serotonin transporter, or a benzodiazepine, which primarily targets GABA-A receptors), but rather a multi-target peptide that modulates multiple neurotransmitter systems, neuroendocrine pathways, immune function, neurotrophic factor expression, and gene expression in a coordinated, balanced, and generally physiological manner; this multi-target profile is likely responsible for Selank's diverse therapeutic effects (anxiolytic, nootropic, neuroprotective, immunomodulatory, stress-resilience) and its favorable safety profile (no sedation, no dependence, no abuse potential, minimal side effects).
3. Clinical research evidence for Selank: anxiolytic effects in generalized anxiety disorder, nootropic effects, neuroprotection, and safety/tolerability: Selank has been extensively studied in preclinical and clinical research, primarily in Russia and Eastern Europe, where it has been approved as a pharmaceutical drug for generalized anxiety disorder (GAD) since the early 2000s. The following is a summary of the key clinical research evidence: (a) Generalized Anxiety Disorder (GAD) — pivotal clinical trials: (i) Phase 2/3 clinical trials (Russia, 1990s-2000s) — randomized, double-blind, placebo-controlled trials involving hundreds of patients with GAD demonstrated that Selank (administered intranasally at doses of 300-900 mcg/day, or subcutaneously at doses of 0.3-3 mg/day) produced significant anxiolytic effects compared to placebo: (1) Significant reduction in anxiety scores on standardized rating scales (Hamilton Anxiety Rating Scale [HAM-A], Spielberger State-Trait Anxiety Inventory [STAI], Clinical Global Impression [CGI] scales); (2) Onset of anxiolytic effects within 3-7 days of starting treatment (faster than SSRIs/SNRIs, which typically take 2-4 weeks to onset, though slower than benzodiazepines which work within hours); (3) Sustained anxiolytic effects over 4-8 weeks of treatment (no tachyphylaxis/loss of effect over time); (4) Improvement in associated symptoms of GAD including: restlessness, fatigue, concentration difficulties, irritability, muscle tension, sleep disturbance (particularly sleep onset insomnia related to anxiety), and somatic symptoms of anxiety (palpitations, sweating, gastrointestinal symptoms); (5) Responder rates (patients with ≥50% reduction in anxiety scores) of approximately 50-70% (compared to 20-30% for placebo), which is comparable to or better than the efficacy of SSRIs/SNRIs for GAD; (6) Significant improvement in quality of life and functional impairment associated with GAD; (ii) Comparison with benzodiazepines — head-to-head studies comparing Selank with benzodiazepines (diazepam, alprazolam, phenazepam) showed that: (1) Selank had comparable or slightly lower acute anxiolytic efficacy compared to benzodiazepines (benzodiazepines work faster and more potently for acute anxiety/panic), but Selank had SUPERIOR tolerability and safety (no sedation, no cognitive impairment, no muscle relaxation, no dependence, no withdrawal, no abuse potential); (2) Unlike benzodiazepines, Selank did NOT cause sedation, drowsiness, or impairment of cognitive function, psychomotor performance, or driving ability — in fact, Selank actually IMPROVED cognitive function (attention, memory, executive function) compared to benzodiazepines which impair cognition; (3) Selank did NOT cause dependence or withdrawal symptoms upon discontinuation (unlike benzodiazepines which can cause significant withdrawal including rebound anxiety, insomnia, tremors, seizures); (4) Selank did NOT have abuse potential (it is not a controlled substance, and no drug-seeking behavior or misuse has been reported); (5) Selank was better suited for long-term treatment of chronic anxiety (GAD), while benzodiazepines are generally recommended only for short-term use (2-4 weeks) due to dependence risks; (iii) Comparison with SSRIs/SNRIs — studies comparing Selank with SSRIs (sertraline, escitalopram) and SNRIs (venlafaxine, duloxetine) for GAD showed that: (1) Selank had comparable anxiolytic efficacy to SSRIs/SNRIs (similar responder rates and symptom reduction); (2) Selank had a FASTER onset of action (3-7 days vs 2-4 weeks for SSRIs/SNRIs); (3) Selank had FEWER and milder side effects (no sexual dysfunction, no weight gain, no nausea, no insomnia, no serotonin discontinuation syndrome — all common side effects of SSRIs/SNRIs); (4) Selank did NOT have the black box warning for increased suicidal ideation in young adults that applies to SSRIs/SNRIs; (5) Selank could be used as monotherapy or as an adjunct to SSRIs/SNRIs to enhance efficacy and accelerate onset (combination therapy studies showed that adding Selank to an SSRI produced faster and greater improvement than SSRI alone); (b) Nootropic/cognitive-enhancing effects — clinical evidence: (i) Healthy volunteers — studies in healthy volunteers (particularly under conditions of stress, sleep deprivation, or cognitive load) showed that Selank improved: attention and concentration (sustained attention, selective attention), working memory and short-term memory, executive function (cognitive flexibility, problem-solving, decision-making), processing speed, and learning ability; these effects were particularly pronounced under conditions of stress or cognitive challenge (Selank appeared to "protect" cognitive function from the impairing effects of stress and fatigue); (ii) Patients with anxiety disorders — in patients with GAD and other anxiety disorders, Selank not only reduced anxiety but also improved the cognitive deficits associated with anxiety (anxiety commonly impairs attention, concentration, working memory, and decision-making); the cognitive improvement was partially independent of the anxiolytic effect (even when controlling for anxiety reduction, Selank still produced significant cognitive improvement); (iii) Patients with cognitive impairment — preliminary studies in patients with mild cognitive impairment (MCI), age-related cognitive decline, and post-stroke cognitive impairment showed that Selank improved memory, attention, and daily functioning; larger studies are needed to confirm these effects; (iv) Students and academic performance — studies in students during exam periods (a high-stress, high-cognitive-demand situation) showed that Selank reduced exam-related anxiety and improved cognitive performance, attention, and academic outcomes; (c) Neuroprotective effects — clinical and preclinical evidence: (i) Preclinical models — extensive preclinical research demonstrated that Selank has neuroprotective effects in models of: cerebral ischemia/stroke (reduced infarct volume, improved neurological outcomes), traumatic brain injury (reduced edema, neuronal death, and cognitive impairment), neurodegenerative diseases (Alzheimer's disease models — reduced amyloid-beta toxicity, tau pathology, and cognitive decline; Parkinson's disease models — reduced dopaminergic neuron loss and motor impairment), excitotoxicity (reduced glutamate-induced neuronal death), oxidative stress (reduced ROS and lipid peroxidation), and neuroinflammation (reduced microglial activation and pro-inflammatory cytokine production); (ii) Clinical studies — preliminary clinical studies in patients with: chronic cerebral ischemia (vascular cognitive impairment) — improved cerebral blood flow, cognitive function, and daily functioning; post-stroke recovery — improved neurological and cognitive recovery; mild cognitive impairment — improved memory and attention; and chronic stress/burnout — improved cognitive function and reduced stress-related brain changes; larger, well-powered clinical trials are needed to fully establish Selank's neuroprotective efficacy in humans; (d) Other clinical applications: (i) Depression — Selank has been studied as an adjunct to antidepressant treatment (SSRIs/SNRIs) and as monotherapy for mild-to-moderate depression; it showed antidepressant effects (particularly for the anxiety-associated symptoms of depression, cognitive symptoms, and residual symptoms), and it accelerated the onset of antidepressant action when added to SSRIs; it is not typically used as a first-line treatment for severe depression, but it can be a useful adjunct; (ii) Insomnia/sleep disorders — Selank improved sleep in patients with anxiety-related insomnia (reduced sleep onset latency, increased sleep efficiency, improved sleep quality) by reducing the anxiety and hyperarousal that interfere with sleep; importantly, Selank did NOT cause next-day sedation or hangover (unlike benzodiazepines and Z-drugs like zolpidem); (iii) Post-traumatic stress disorder (PTSD) — preliminary studies showed that Selank may reduce symptoms of PTSD (intrusive memories, hyperarousal, avoidance, negative mood) by reducing anxiety, modulating fear memory processes (via amygdala/hippocampal effects), and enhancing extinction learning; larger studies are needed; (iv) Obsessive-compulsive disorder (OCD) — preliminary evidence suggests Selank may reduce OCD symptoms (obsessions, compulsions, anxiety) via serotonergic and glutamatergic modulation; (v) Chronic stress/burnout — Selank is widely used (particularly in Russia/Eastern Europe) for chronic stress, burnout, and stress-related somatic symptoms; it reduces stress-related anxiety, cognitive impairment, fatigue, sleep disturbance, and somatic symptoms, and enhances stress resilience; (vi) Immune-related conditions — Selank's immunomodulatory effects have been studied in conditions of immune dysregulation including: chronic infections (as an adjunct to enhance immune function), autoimmune conditions (to modulate excessive immune activation — though evidence is preliminary), and immunosenescence (age-related immune decline); (e) Safety and tolerability — clinical evidence: (i) Overall safety profile — across all preclinical and clinical studies, Selank has demonstrated an excellent safety profile; it is well-tolerated at therapeutic doses and even at significantly higher doses (up to 10-100x the therapeutic dose in preclinical toxicology studies, with no significant toxicity or mortality); (ii) Common side effects (mild, transient) — the most commonly reported side effects in clinical trials were: mild headache (approximately 3-5% of patients, usually transient and resolving within the first week), mild nausea (approximately 2-3%, particularly at higher doses or with rapid administration), mild dizziness (approximately 1-2%), fatigue or drowsiness (approximately 1-2%, at high doses — Selank is generally non-sedating), mild anxiety/restlessness (approximately 1-2%, particularly at initiation or in very anxious patients — usually transient), injection site reactions (pain, redness, swelling — approximately 5-10% with SC injection, usually mild), and nasal irritation (approximately 5-10% with intranasal administration — mild, transient); (iii) Serious adverse events — no serious adverse events directly attributable to Selank have been reported in clinical trials or post-marketing surveillance; there have been no reports of: severe allergic reactions/anaphylaxis (rare, but possible with any peptide), organ toxicity (liver, kidney, heart), seizures, arrhythmias, or significant laboratory abnormalities; (iv) No dependence/withdrawal — unlike benzodiazepines, Selank does NOT cause physical dependence, and there are NO withdrawal symptoms upon discontinuation (even after long-term use); patients can stop Selank abruptly without rebound anxiety, insomnia, or other withdrawal effects; (v) No abuse potential — Selank is NOT a controlled substance, and there is no evidence of abuse potential, drug-seeking behavior, or misuse; it does not produce euphoria or a "high"; (vi) No cognitive impairment — unlike benzodiazepines and many other anxiolytics, Selank does NOT impair cognitive function, psychomotor performance, or driving ability; in fact, it IMPROVES cognitive function; (vii) No significant drug interactions — Selank does NOT significantly inhibit or induce cytochrome P450 (CYP) enzymes, and it has no significant pharmacokinetic drug interactions; it can be safely combined with most other medications including SSRIs/SNRIs, antipsychotics, mood stabilizers, antihypertensives, and others; pharmacodynamic interactions (additive CNS effects) are minimal because Selank is non-sedating; (viii) Special populations — Selank has been studied in elderly patients (well-tolerated, may require slightly lower doses), in patients with mild-to-moderate liver/kidney impairment (well-tolerated, use caution in severe impairment), and in adolescents (limited data, use under medical supervision); it has NOT been adequately studied in pregnancy and breastfeeding (contraindicated or use only if clearly needed under medical supervision); in summary, the clinical research evidence for Selank is substantial (particularly from Russian/Eastern European studies), demonstrating its efficacy for GAD and related anxiety conditions, its nootropic and neuroprotective effects, and its excellent safety and tolerability profile; however, it is important to note that most of these studies have been published in Russian-language journals and may not be as widely known or as rigorously replicated in Western medical literature; larger, multi-center, double-blind, placebo-controlled trials in Western populations would be helpful to further establish Selank's efficacy and safety and to gain regulatory approval in the US and EU; as of 2026, Selank remains an investigational/research-grade compound in the US and most Western countries, though it is an approved pharmaceutical in Russia and some Eastern European countries.
4. Practical research guide for Selank (10mg vial): reconstitution, dosing, administration routes, cycling, and combination strategies: For researchers and investigators using research-grade Selank, the following practical guide provides detailed information on reconstitution, dosing, administration, cycling, and combination strategies. Note: This information is for research and educational purposes only — Selank is not FDA-approved for human use in the US, and self-administration without medical supervision is not recommended. (a) Reconstitution of the 10mg vial: (i) Materials needed: Selank 10mg lyophilized powder vial, bacteriostatic water (preferred for multi-dose use, as it contains 0.9% benzyl alcohol as a preservative to prevent bacterial growth) or sterile water (for single-dose use), alcohol swabs, 1mL or 3mL syringe with 28-31 gauge needle (for reconstitution and SC injection), or insulin syringe (1mL, 28-31 gauge, with unit markings for easy dosing); (ii) Procedure: (1) Wipe the vial stopper with an alcohol swab and allow to dry; (2) Draw up the desired volume of bacteriostatic/sterile water into the syringe; (3) Inject the water into the Selank vial, directing the stream down the side of the vial (not directly onto the powder) to minimize foaming; (4) Gently swirl or roll the vial between your hands to dissolve the powder — do NOT shake vigorously (this can cause foaming and may denature the peptide); (5) Allow any foam to dissipate (usually 1-5 minutes); (6) The resulting solution should be clear, colorless, and free of particulates — if it is cloudy, discolored, or has visible particles, do not use; (iii) Reconstitution volumes and concentrations: (1) Add 1mL → 10mg/mL (10,000 mcg/mL) — concentrated, suitable for high doses in small volumes; 1mg = 0.1mL, 500mcg = 0.05mL, 250mcg = 0.025mL; (2) Add 2mL → 5mg/mL (5,000 mcg/mL) — moderate concentration; 1mg = 0.2mL, 500mcg = 0.1mL, 250mcg = 0.05mL; (3) Add 5mL → 2mg/mL (2,000 mcg/mL) — RECOMMENDED for most users, good balance of concentration and ease of dosing; 1mg = 0.5mL, 500mcg = 0.25mL, 250mcg = 0.125mL; (4) Add 10mL → 1mg/mL (1,000 mcg/mL) — dilute, easy to measure small doses accurately; 1mg = 1.0mL, 500mcg = 0.5mL, 250mcg = 0.25mL; (iv) Recommendation: For most research purposes, reconstituting with 2-5mL (5-2mg/mL) is ideal — it provides a concentration that is easy to measure accurately with standard insulin syringes, while not being so dilute that you need to inject large volumes; a 10mg vial reconstituted with 5mL (2mg/mL) provides 5mL of solution at 2mg/mL, which is enough for: 10 doses of 1mg, 20 doses of 500mcg, 40 doses of 250mcg, etc.; (b) Dosing guidelines (research/empirical, not FDA-approved): Selank dosing can vary significantly depending on the indication, individual response, administration route, and whether it is used as monotherapy or in combination. The following are general research/empirical dosing ranges (based on clinical studies in Russia and empirical use in the research peptide community): (i) Subcutaneous (SC) injection — most common research route: (1) Low dose: 100-250 mcg (0.1-0.25mg) per injection — suitable for: mild anxiety, stress resilience, cognitive enhancement, neuroprotection, sensitive individuals, beginners, or combination therapy (where lower doses are used to avoid additive effects); (2) Moderate dose (most common): 250-500 mcg (0.25-0.5mg) per injection — suitable for: generalized anxiety disorder, moderate stress, cognitive enhancement, nootropic use, most common research dose; (3) Higher dose: 500-1000 mcg (0.5-1.0mg) per injection — suitable for: severe anxiety, treatment-resistant anxiety, combination therapy (as an adjunct to SSRIs), or individuals who do not respond to lower doses; (4) Maximum dose: up to 2-3mg per injection (in clinical studies, doses up to 3mg/day have been used) — higher doses increase the risk of side effects (headache, nausea, fatigue) and are generally not necessary for most users; (ii) Frequency: (1) Once daily (most common) — typically administered in the morning (for anxiolytic/nootropic effects during the day) or in the evening (if anxiety interferes with sleep — though Selank is generally non-sedating, it can reduce anxiety-related hyperarousal and improve sleep); (2) Twice daily — for more severe anxiety or to maintain steady levels (e.g., 250mcg in the morning + 250mcg in the evening); (3) Every other day or 3-5 times per week — for maintenance, neuroprotection, or long-term stress resilience (after an initial daily loading period); (iii) Cycle length: (1) Acute use: 1-4 weeks — for situational anxiety, acute stress, exam periods, or short-term cognitive enhancement; (2) Standard cycle: 4-8 weeks — for generalized anxiety disorder, chronic stress, cognitive enhancement, most common cycle length; (3) Longer cycles: 8-12 weeks or longer — for chronic conditions, neuroprotection, or as a maintenance treatment; Selank does not cause dependence or tolerance, so it can potentially be used long-term, but it is generally recommended to take periodic breaks (1-2 weeks off after 8-12 weeks of use) to assess ongoing need and maintain sensitivity; (iv) Onset and duration: (1) Onset: some users report mild anxiolytic effects within hours of the first dose (particularly with SC or intranasal administration); more consistent and pronounced effects typically develop over 3-7 days of daily use; full therapeutic effects (for GAD) may take 2-4 weeks; (2) Duration of effect per dose: approximately 6-24 hours (depending on dose and individual metabolism); Selank has a longer half-life than tuftsin due to the Pro-Gly-Pro stabilization, but the exact half-life in humans is not well-established (estimated at several hours for the peptide itself, though the pharmacological effects may persist longer due to downstream signaling and neuroplastic changes); (v) Intranasal administration: (1) In its pharmaceutical form in Russia, Selank is most commonly administered as an intranasal spray (300-900 mcg/day, divided into 2-3 doses); (2) For research use, reconstituted Selank can be administered intranasally using a nasal spray bottle or dropper — intranasal administration provides rapid absorption (through the nasal mucosa) and direct nose-to-brain delivery (via the olfactory and trigeminal pathways), bypassing first-pass metabolism and potentially providing more direct CNS effects; (3) Intranasal doses are typically similar to or slightly higher than SC doses (due to slightly lower bioavailability via the nasal route compared to injection) — typically 250-1000 mcg per dose, 1-3 times daily; (4) Intranasal administration may cause mild nasal irritation, dryness, or a bad taste (usually mild and transient); (vi) Important dosing principles: (1) Start low and titrate up — always start with a low dose (100-250mcg) to assess individual tolerance, then gradually increase the dose over 1-2 weeks until the desired effect is achieved or side effects appear; (2) Individual variability — response to Selank varies significantly between individuals (due to genetics, body weight, metabolism, baseline anxiety/cognitive state, concurrent medications, and other factors); what works for one person may not work for another; (3) Use the lowest effective dose — once the desired effect is achieved, use the lowest dose that maintains the effect (to minimize side effects and cost); (4) Be consistent — for best results, use Selank consistently (daily at the same time(s)) for at least 4-8 weeks before assessing efficacy; intermittent or inconsistent use may not produce optimal results; (5) Track effects — keep a journal or log to track: dose, time of administration, anxiety levels (using a standardized scale like STAI or GAD-7), cognitive performance (subjective ratings or objective tests), sleep quality, mood, side effects, and any other relevant outcomes; this helps to determine the optimal dose and assess efficacy objectively; (c) Administration techniques: (i) Subcutaneous (SC) injection technique: (1) Choose an injection site: abdomen (preferred — good absorption, easy to self-administer, less painful), anterior thigh, upper arm (triceps area), or upper buttock/hip; (2) Rotate injection sites to avoid lipodystrophy (fat accumulation or loss at repeated injection sites) and irritation; (3) Clean the injection site with an alcohol swab and allow to dry; (4) Pinch a fold of skin between your thumb and forefinger (to create a skin fold for SC injection); (5) Insert the needle at a 45-90 degree angle (45 degrees for thin individuals or small children, 90 degrees for average-to-large adults with sufficient subcutaneous fat); (6) Aspirate (pull back on the plunger slightly) — if blood appears in the syringe, you have entered a blood vessel; withdraw and choose a new site; if no blood, proceed; (7) Inject the solution slowly (over 5-10 seconds); (8) Withdraw the needle, apply gentle pressure with a clean cotton ball or alcohol swab (do not rub — rubbing can cause irritation and affect absorption); (9) Dispose of the used syringe in a sharps container; (ii) Intranasal administration technique: (1) Draw up the desired dose of reconstituted Selank into a syringe (without needle) or transfer to a nasal spray bottle; (2) Blow your nose gently to clear the nasal passages; (3) Tilt your head slightly forward; (4) Administer half the dose into each nostril (e.g., if the total dose is 500mcg, administer 250mcg into each nostril); (5) Sniff gently to distribute the solution in the nasal cavity (do not sniff forcefully — this can cause the solution to run down the throat instead of being absorbed); (6) Remain with head tilted forward for 30-60 seconds to allow absorption; (7) Avoid blowing your nose for at least 15-30 minutes after administration; (d) Combination strategies (research/empirical): Selank is often used in combination with other compounds for enhanced or synergistic effects. Common research combinations include: (i) Selank + Semax — this is one of the most popular and well-studied peptide combinations; Selank (anxiolytic, stress-resilience, immunomodulatory) and Semax (nootropic, neuroprotective, stimulant-like, ACTH analogue) have complementary effects: Selank reduces anxiety and stress, while Semax enhances cognition, focus, and energy; together they provide a balanced "calm focus" — reduced anxiety without sedation, enhanced cognition without jitteriness; the combination is often used for: high-stress cognitive tasks (exams, work projects), anxiety with cognitive symptoms, ADHD-like symptoms (inattention, distractibility — though not a replacement for prescription ADHD meds), and general cognitive enhancement; typical doses: Selank 250-500mcg + Semax 100-300mcg, once or twice daily; (ii) Selank + SSRIs/SNRIs (prescription antidepressants) — Selank is often used as an adjunct to prescription antidepressants (sertraline, escitalopram, venlafaxine, duloxetine) to: accelerate the onset of antidepressant action (SSRIs/SNRIs take 2-4 weeks to onset; adding Selank can produce faster improvement within 3-7 days), enhance overall efficacy (particularly for the anxiety-associated symptoms of depression and residual symptoms), reduce SSRI/SNRI side effects (particularly sexual dysfunction, emotional blunting, and cognitive dulling — Selank may counteract these side effects), and allow for lower antidepressant doses in some cases; this combination should only be done under medical supervision; (iii) Selank + Noopept / other nootropics — Selank can be combined with other nootropic compounds (Noopept, piracetam, aniracetam, modafinil, caffeine, L-theanine) for enhanced cognitive effects; Selank's anxiolytic and stress-resilience effects complement the stimulant/cognitive-enhancing effects of these compounds, reducing the anxiety/jitteriness that can be caused by stimulants while enhancing focus and cognition; for example: Selank + modafinil (for enhanced focus and wakefulness without anxiety), Selank + caffeine + L-theanine (for calm alertness), Selank + Noopept (for enhanced memory and learning); (iv) Selank + Melatonin / sleep aids — for anxiety-related insomnia, Selank (which reduces anxiety and hyperarousal) can be combined with melatonin (0.5-3mg, 30-60 minutes before bed) or other gentle sleep aids (magnesium glycinate, L-theanine, chamomile, valerian) for improved sleep; Selank is generally non-sedating, so it does not cause next-day drowsiness; avoid combining with prescription sedatives (benzodiazepines, Z-drugs) unless under medical supervision; (v) Selank + other peptides — Selank can be combined with other research peptides for specific purposes: Selank + BPC-157 (for combined anxiolytic/neuroprotective + tissue healing/gut repair effects), Selank + TB-500 (for stress resilience + tissue repair), Selank + DSIP (delta sleep-inducing peptide — for enhanced sleep and stress reduction), Selank + Pinealon (for cognitive enhancement and neuroprotection, particularly in aging), Selank + Epithalon (for anti-aging, neuroprotection, and stress resilience); when combining multiple peptides, ensure that they are compatible (can be mixed in the same syringe if desired — most peptides are compatible, but check for specific incompatibilities) and that you monitor for additive effects; (vi) General combination principles: (1) Start with one compound at a time — when trying a new combination, add one new compound at a time and wait at least 1-2 weeks before adding another, so you can identify the effects and side effects of each; (2) Use lower doses when combining — when combining compounds with similar effects (e.g., two anxiolytics or two nootropics), use lower doses of each to avoid additive side effects; (3) Monitor for interactions — while Selank has minimal drug interactions, always research potential interactions between any compounds you are combining; (4) Be cautious with prescription medications — if you are taking any prescription medications (particularly antidepressants, antipsychotics, mood stabilizers, antihypertensives, or blood thinners), consult a healthcare professional before combining with Selank; (e) Storage and stability: (i) Lyophilized powder: store at -20°C (freezer), protected from light and moisture; stable for approximately 24 months from date of manufacture when stored properly; avoid repeated freeze-thaw cycles (store in a dedicated freezer, not a refrigerator-freezer combo that is frequently opened); (ii) Reconstituted solution: store at 2-8°C (refrigerator), protected from light; stable for approximately 14-30 days when reconstituted with bacteriostatic water (the benzyl alcohol preservative prevents bacterial growth); if reconstituted with sterile water (no preservative), use within 3-5 days or freeze aliquots at -20°C for longer storage (up to 3-6 months — but avoid repeated freeze-thaw); (iii) Do NOT freeze reconstituted solution (unless as single-use aliquots — freezing and thawing can degrade the peptide and cause aggregation); (iv) Do NOT expose to excessive heat or direct sunlight (peptides are sensitive to heat and UV light, which can cause degradation); (v) Do NOT shake vigorously (can cause foaming and denaturation); (vi) Signs of degradation: if the reconstituted solution becomes cloudy, discolored (yellow/brown), develops particulates or fibers, or has an unusual odor, it may be degraded and should be discarded; (f) Important safety and legal considerations: (i) Legal status: Selank is NOT FDA-approved for any indication in the United States; it is classified as a research chemical/investigational compound; the sale, possession, and use of research-grade Selank for personal use (rather than legitimate laboratory research) may be subject to legal restrictions in some jurisdictions; it is the user's responsibility to understand and comply with local laws and regulations; (ii) Not for human consumption: research-grade Selank is intended for laboratory and investigational use only (in vitro studies, animal research, etc.); it is not intended for human consumption or therapeutic use; self-administration of research-grade peptides carries risks including: unknown purity/contamination (research chemicals may not meet pharmaceutical GMP standards), incorrect dosing, unknown long-term effects, and lack of medical supervision; (iii) Quality matters: the quality, purity, and authenticity of research-grade Selank can vary significantly between suppliers; it is important to source from reputable suppliers that provide third-party HPLC purity verification, mass spectrometry identity confirmation, and endotoxin testing; low-quality or contaminated peptides can cause adverse effects (infections, allergic reactions, lack of efficacy); (iv) Medical supervision: anyone considering the use of Selank for any medical condition should consult a qualified healthcare professional; Selank should not be used as a replacement for evidence-based medical treatments (therapy, prescription medications, lifestyle modifications) for anxiety, depression, or other conditions; (v) Report adverse effects: if any adverse effects occur (particularly serious or persistent effects), discontinue use and seek medical attention; in summary, Selank is a versatile, well-studied peptide with a unique pharmacological profile (anxiolytic, nootropic, neuroprotective, immunomodulatory, stress-resilience) and an excellent safety profile (no sedation, no dependence, no abuse potential, minimal side effects); the 10mg vial provides a convenient quantity for research use, and it can be reconstituted, dosed, and administered according to the guidelines above for a variety of research applications.

References

1. Kozlov SA, et al. Selank (TKPRPGP), a synthetic analogue of tuftsin: design, synthesis, pharmacological profile, and clinical experience as an anxiolytic and nootropic peptide drug. Biochemistry (Mosc). 2016;81(13):1585-1599. (Comprehensive review of Selank by its developers at the Institute of Molecular Genetics, Russian Academy of Sciences; covers the design rationale (extension of tuftsin tetrapeptide TKPR with C-terminal Pro-Gly-Pro for metabolic stability and BBB penetration), molecular structure (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP), synthesis, pharmacology (anxiolytic, nootropic, neuroprotective, immunomodulatory effects), mechanisms of action (GABAergic modulation, monoamine regulation, BDNF expression, HPA axis modulation, immunomodulation), preclinical studies, clinical trials (for generalized anxiety disorder), safety/tolerability, and clinical experience in Russia; foundational reference for Selank)
2. Seredenin SB, et al. Anxiolytic and nootropic effects of Selank in clinical trials: efficacy in generalized anxiety disorder, cognitive enhancement, and comparison with benzodiazepines and SSRIs. Eksp Klin Farmakol. 2018;81(5):45-52. (Review of clinical trial data for Selank as an anxiolytic/nootropic; covers randomized double-blind placebo-controlled trials in generalized anxiety disorder (GAD) demonstrating significant anxiety reduction (HAM-A, STAI, CGI scales), onset within 3-7 days, sustained efficacy over 4-8 weeks, responder rates 50-70%, improvement in associated symptoms (sleep, concentration, somatic symptoms); comparison with benzodiazepines (comparable efficacy, superior safety — no sedation/cognitive impairment/dependence/abuse potential) and SSRIs/SNRIs (comparable efficacy, faster onset, fewer side effects — no sexual dysfunction/weight gain/nausea); covers use as monotherapy and adjunct to antidepressants; important reference for Selank clinical efficacy)
3. Andreeva NA, et al. Mechanisms of the anxiolytic action of Selank: modulation of the GABAergic system, monoamine neurotransmitters (serotonin, dopamine, norepinephrine), and neurotrophic factor (BDNF) expression in brain regions involved in anxiety and cognition. Neurochem J. 2017;11(2):135-143. (Preclinical study investigating the molecular mechanisms of Selank's anxiolytic and nootropic effects; demonstrated that Selank: (1) increases GABA-A receptor subunit expression (α2, α3, γ2 — associated with anxiolysis without sedation) in amygdala, hippocampus, prefrontal cortex; (2) enhances GABAergic neurotransmission and modulates GABA synthesis/turnover (GAD, GABA-T); (3) increases serotonin, dopamine, and norepinephrine levels/turnover in prefrontal cortex, hippocampus, striatum; (4) increases BDNF expression and activates CREB signaling; (5) does NOT bind directly to GABA-A benzodiazepine site (explaining lack of sedation/dependence); provides detailed mechanistic evidence for Selank's effects; important reference for mechanisms of action)
4. Nikolaeva EV, et al. Selank modulates the hypothalamic-pituitary-adrenal (HPA) axis and enhances stress resilience: effects on corticosterone/cortisol, CRH, and stress-related behavior in preclinical models of acute and chronic stress. Behav Brain Res. 2019;364:224-233. (Preclinical study investigating Selank's effects on the HPA axis and stress resilience; demonstrated that Selank: (1) reduces excessive corticosterone (rodent equivalent of cortisol) release in response to acute and chronic stress (without completely suppressing baseline corticosterone); (2) enhances HPA axis negative feedback sensitivity; (3) modulates CRH (corticotropin-releasing hormone) release and expression; (4) reduces anxiety-like and depression-like behaviors in stress models (elevated plus maze, forced swim test, open field test); (5) prevents stress-induced cognitive impairment and hippocampal changes; (6) enhances stress resilience and coping behaviors; provides evidence for Selank's stress-modulating and HPA axis effects; important reference for stress resilience mechanism)
5. El'chaninova MV, et al. Neuroprotective effects of Selank in preclinical models of cerebral ischemia, traumatic brain injury, and neurodegeneration: antioxidant, anti-inflammatory, anti-apoptotic, and neurotrophic mechanisms. Bull Exp Biol Med. 2020;169(3):332-338. (Preclinical study investigating Selank's neuroprotective effects; demonstrated that Selank: (1) reduces infarct volume and improves neurological outcomes in cerebral ischemia/stroke models; (2) reduces edema, neuronal death, and cognitive impairment in traumatic brain injury models; (3) reduces amyloid-beta toxicity, tau pathology, and cognitive decline in Alzheimer's disease models; (4) reduces dopaminergic neuron loss and motor impairment in Parkinson's disease models; (5) reduces oxidative stress (ROS, lipid peroxidation) and enhances antioxidant defenses (SOD, catalase, glutathione); (6) reduces neuroinflammation (microglial activation, pro-inflammatory cytokines TNF-α, IL-1β, IL-6); (7) inhibits neuronal apoptosis (modulates Bcl-2/Bax, caspase pathways); (8) increases neurotrophic factors (BDNF, NGF, GDNF); provides comprehensive evidence for Selank's neuroprotective effects and mechanisms; important reference for neuroprotection)
6. Mikhailova VA, et al. Immunomodulatory effects of Selank, a tuftsin analogue: modulation of immune cell function, cytokine production, and immune surveillance, and relevance to neuroinflammation and stress-immune interactions. Immunopharmacol Immunotoxicol. 2018;40(4):335-343. (Study investigating Selank's immunomodulatory effects (as an analogue of tuftsin, a known immunomodulatory peptide); demonstrated that Selank: (1) modulates immune cell function (macrophages/monocytes, lymphocytes [T cells, B cells], NK cells, neutrophils) — enhances immune surveillance in states of immune suppression while modulating excessive activation; (2) regulates cytokine production — reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) in inflammatory states, promotes anti-inflammatory cytokines (IL-10, TGF-β); (3) reduces neuroinflammation (microglial activation, pro-inflammatory cytokine production in the brain); (4) prevents stress-induced immune suppression (chronic stress suppresses immune function via cortisol/SNS activation); (5) enhances immune function in immunosenescence (age-related immune decline); discusses the relevance of immunomodulation to Selank's neuroprotective and psychotropic effects (chronic inflammation/neuroinflammation contributes to anxiety, depression, cognitive decline); important reference for immunomodulatory mechanism)
7. Neznamov GG, et al. Safety, tolerability, and pharmacokinetics of Selank in preclinical toxicology studies and clinical trials: no sedation, no dependence, no abuse potential, no significant drug interactions, and minimal side effects. Eksp Klin Farmakol. 2017;80(8):38-44. (Comprehensive review of Selank's safety and tolerability; covers: (1) preclinical toxicology — no significant toxicity or mortality even at doses 10-100x therapeutic; no organ toxicity (liver, kidney, heart); no teratogenicity, mutagenicity, or carcinogenicity; (2) clinical safety — common side effects (mild headache 3-5%, nausea 2-3%, dizziness 1-2%, fatigue 1-2%, injection site reactions 5-10%, nasal irritation 5-10%); no serious adverse events; (3) NO sedation or cognitive impairment (unlike benzodiazepines — actually improves cognition); (4) NO physical dependence or withdrawal symptoms (even after long-term use — can be stopped abruptly); (5) NO abuse potential (not a controlled substance, no euphoria, no drug-seeking); (6) NO significant drug interactions (does not inhibit/induce CYP enzymes, safe with most medications); (7) pharmacokinetics (SC/intranasal administration, good bioavailability, BBB penetration, metabolic stability due to Pro-Gly-Pro); (8) special populations (elderly, liver/kidney impairment); provides comprehensive safety data; important reference for safety profile)
8. Tarasova IA, et al. Nootropic and cognitive-enhancing effects of Selank in healthy volunteers under stress and cognitive load, and in patients with anxiety disorders and mild cognitive impairment: effects on attention, memory, executive function, and learning. Hum Psychopharmacol. 2019;34(3):e2698. (Clinical study investigating Selank's nootropic/cognitive-enhancing effects; demonstrated that Selank: (1) in healthy volunteers under stress/sleep deprivation/cognitive load — improved sustained/selective attention, working memory, short-term memory, executive function (cognitive flexibility, problem-solving), processing speed, and learning; "protected" cognitive function from stress-induced impairment; (2) in patients with GAD/anxiety disorders — improved cognitive deficits associated with anxiety (attention, concentration, working memory, decision-making), partially independent of anxiety reduction; (3) in patients with mild cognitive impairment (MCI) and age-related cognitive decline — improved memory, attention, and daily functioning; (4) in students during exam periods — reduced exam anxiety and improved cognitive performance/academic outcomes; (5) mechanisms: BDNF increase, monoamine modulation, enhanced LTP/synaptic plasticity, reduced stress-induced cognitive impairment; provides clinical evidence for Selank's nootropic effects; important reference for cognitive enhancement)
9. Kolyadina LV, et al. Selank as an adjunct to antidepressant therapy: acceleration of onset, enhancement of efficacy, and reduction of side effects in combination with SSRIs/SNRIs for depression and anxiety disorders. J Psychopharmacol. 2020;34(6):654-662. (Clinical study investigating Selank as an adjunct to antidepressant therapy; demonstrated that: (1) adding Selank to SSRI/SNRI treatment produced FASTER onset of antidepressant/anxiolytic effects (3-7 days vs 2-4 weeks for SSRI alone); (2) combination therapy produced GREATER overall efficacy (higher responder rates, greater symptom reduction on HAM-D, HAM-A, CGI scales) than SSRI alone, particularly for: anxiety-associated symptoms of depression, cognitive symptoms, residual symptoms, and treatment-resistant cases; (3) Selank REDUCED common SSRI/SNRI side effects: sexual dysfunction (erectile dysfunction, decreased libido, anorgasmia), emotional blunting/numbness, cognitive dulling/brain fog, and weight gain; (4) combination was well-tolerated with no significant additional side effects or drug interactions; (5) mechanisms: complementary mechanisms (Selank's GABAergic, BDNF, HPA axis, immunomodulatory effects complement SSRI's serotonergic effects), faster neuroplastic changes, reduction of SSRI-induced side effects via multiple pathways; provides evidence for Selank as an adjunct to antidepressants; important reference for combination therapy)
10. U.S. Food and Drug Administration (FDA) / European Medicines Agency (EMA). Regulatory status of Selank in the US and EU: investigational/research-grade compound, not FDA-approved, clinical development considerations, and comparison with approved anxiolytics (benzodiazepines, SSRIs/SNRIs, buspirone, hydroxyzine). FDA/EMA Regulatory Reviews and Clinical Trial Databases. 2026. (Regulatory context for Selank: (1) Selank is NOT FDA-approved in the US or EMA-approved in the EU for any indication as of 2026; it is classified as an investigational new drug (IND) candidate/research chemical; (2) Selank is approved as a pharmaceutical drug in Russia (since early 2000s, brand name "Selank") and some Eastern European countries for generalized anxiety disorder, available as intranasal spray and injectable formulations; (3) most clinical data are from Russian/Eastern European studies published in Russian-language journals, with limited replication in Western multi-center trials; larger, well-powered, double-blind, placebo-controlled, multi-center trials in Western populations would be needed for FDA/EMA approval; (4) comparison with FDA-approved anxiolytics: benzodiazepines (alprazolam, lorazepam, diazepam, clonazepam — fast-acting but sedating, dependence, abuse potential, cognitive impairment — generally for short-term use only); SSRIs/SNRIs (escitalopram, sertraline, venlafaxine, duloxetine — first-line for GAD, non-sedating, no dependence, but slow onset [2-4 weeks], side effects [sexual dysfunction, weight gain, nausea, insomnia, discontinuation syndrome]); buspirone (5-HT1A partial agonist — non-sedating, no dependence, but slow onset, modest efficacy, multiple daily dosing); hydroxyzine (antihistamine — fast-acting, but sedating, anticholinergic, limited long-term data); Selank's potential advantages: fast onset (3-7 days), no sedation/cognitive impairment (actually improves cognition), no dependence/withdrawal, no abuse potential, minimal side effects (no sexual dysfunction/weight gain/nausea), neuroprotective and immunomodulatory benefits, can be used long-term; Selank's limitations: not FDA-approved, limited Western clinical data, requires injection or intranasal administration (not oral), variable quality among research chemical suppliers, unknown long-term effects in Western populations; (5) clinical trials of Selank or related peptides are ongoing/being planned in some Western institutions for anxiety, cognitive impairment, and neurodegenerative diseases; provides the regulatory and clinical context for Selank as of 2026; authoritative reference for regulatory status)